The GLP-1 Coverage Decision: The Spend Shock Saudi Insurers Cannot Improvise

There is a category of strategic decision that becomes harder, not easier, the longer it is deferred, because the market moves while the decision waits. The coverage of GLP-1 receptor agonists is now that decision for Saudi health insurers. The drugs are here. The demand is enormous and growing. The clinical evidence base is expanding in a direction that makes exclusion progressively harder to defend. And the cost, if coverage is granted without a framework, is among the largest and least controllable pharmacy exposures any payer in the world currently faces. An insurer that has not made a deliberate, structured decision about GLP-1 coverage does not therefore have no policy. It has an accidental policy, made by default, in a situation that will not stay still long enough for default to remain safe.

Consider the demand that already exists. Adult obesity in Saudi Arabia stands at 23.1%, with a further 42.6% of the population overweight. In one Eastern Province study of overweight and obese adults, 18.2% reported having used a GLP-1, and 14.2% were current users, with injectable semaglutide the most common. Awareness is near-universal: separate Saudi surveys report GLP-1 awareness between 73% and 93%, with social media the most common information source and weight reduction, not diabetes, the most common reason for use. This is a population that is already taking these drugs, largely funding them privately, and increasingly asking why their insurance does not cover a treatment their physician supports and their neighbour is using.

Now consider what is happening to the drugs themselves. GLP-1 receptor agonists began as diabetes treatments. Their weight-loss effect moved them into obesity management, a category many payers globally treat as elective and exclude. But the SELECT trial changed the terms of that argument. In 17,604 overweight patients with established cardiovascular disease and no diabetes, semaglutide reduced major adverse cardiovascular events by 20% over a median follow-up of around 42 months. That result reclassifies the drug. A medication that prevents heart attacks and strokes in a high-risk population is not straightforwardly a lifestyle product. As the evidence base broadens, from diabetes, to obesity, to cardiovascular protection, and increasingly to kidney and other outcomes, the ground on which an insurer might exclude these drugs as cosmetic is eroding underneath the decision.

Why This Is a Decision and Not a Formulary Update

The instinct in many organisations is to treat GLP-1 coverage as a pharmacy question, resolved by adding or declining a drug on a formulary. That instinct understates it. The GLP-1 coverage decision is a strategic decision with actuarial, clinical, and reputational dimensions that a formulary line cannot contain, because of the specific combination of characteristics these drugs possess.

They are expensive, at a level that persists. Without coverage, GLP-1 therapy commonly costs well over USD 1,000 per month internationally, and while manufacturers are beginning to reduce list prices, the drugs are taken for extended periods, potentially indefinitely, because weight is regained when they stop. The cost is therefore not a one-time event but a recurring, compounding liability across a large eligible population. When the eligible population is 23.1% of adults for obesity alone, before overweight-with-comorbidity is added, the budget impact of an unrestricted coverage decision is measured in proportions of total pharmacy spend that can reshape a payer's economics.

They are also subject to a demand dynamic unlike most pharmacy categories. Demand is driven not only by clinical referral but by consumer awareness, social media, and cultural momentum. This means utilisation can rise faster than a payer's models, built on traditional prescribing patterns, would predict. And the clinical picture carries its own governance complexity: high discontinuation rates, weight regain on cessation, variable response, and the question of what happens to spend and outcomes when a member stops. A coverage decision that does not address discontinuation conditions, response criteria, and stopping rules is a decision that has not confronted the actual clinical behaviour of the therapy.

The Lesson From Markets That Decided Under Pressure

Saudi insurers have one significant advantage: they are making this decision with the benefit of watching other markets make it first, often badly. The international experience is a case study in the cost of deciding without a framework.

In the United States, coverage has been volatile and contested. Many employer and marketplace plans exclude GLP-1s for obesity while covering them for diabetes, producing the situation where the same molecule is covered or denied depending on the diagnosis code. By 2026, only a small minority of marketplace plans covered GLP-1s for obesity, and that number was reported to be shrinking under cost pressure. Public programmes have oscillated, with weight-loss indications historically excluded and now the subject of pilots and phased approaches. Formularies have swung, with major pharmacy benefit managers adding, dropping, and re-adding these drugs as they negotiate prices, disrupting patients mid-treatment. The budget projections are sobering: independent analysis put the cost of one public programme covering anti-obesity medications at tens of billions over a decade. The lesson is not that coverage is wrong or that exclusion is wrong. The lesson is that deciding without a rigorous framework, and then reversing under financial or political pressure, is the most expensive and least credible path of all.

The Structure of a Defensible Decision

A defensible GLP-1 coverage decision is not a yes or a no. It is a structured position across several dimensions, each of which must be deliberately set rather than left implicit. This is the work most organisations have not done, and it is precisely the kind of structured decision that rewards a framework.

Each of these dimensions is a decision in itself, and they interact. A generous coverage criterion with weak prior authorisation and no discontinuation conditions is a very different, and far more expensive, position than the same criterion with rigorous clinical gating. An organisation that sets one dimension without the others has not made a coherent decision. It has made a partial one, and the gaps are where the uncontrolled cost or the reputational exposure enters.

The Decision That Will Not Wait

The distinctive feature of the GLP-1 coverage decision is its combination of urgency and irreversibility. It is urgent because the demand is present now, the prescribing is happening now, and members are already absorbing costs and forming expectations. It resists reversal because a coverage position, once set and communicated, is difficult and reputationally costly to withdraw, as the markets that have tried have discovered. And it is consequential at a scale, given the eligible population and the price, that few other single pharmacy decisions match.

This is why the decision rewards structure over instinct. An insurer that frames the decision deliberately, models it rigorously, sets each dimension of the position coherently, and builds in a mechanism to adjust as the evidence moves, is making a decision it can defend to its board, its regulator, and its members. An insurer that adds or declines the drug on a formulary and hopes the question does not escalate is making a decision it will very likely have to remake, under worse conditions, later. The GLP-1 question is not going to resolve itself. The only choice is whether to decide it deliberately or to have it decided by default.